<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886533</url>
  </required_header>
  <id_info>
    <org_study_id>35RC12_8986_SACHA</org_study_id>
    <nct_id>NCT02886533</nct_id>
  </id_info>
  <brief_title>Major Bleeding Risk Associated With Antithrombotics</brief_title>
  <acronym>SACHA</acronym>
  <official_title>Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, observational study with a three-year inclusion period (from
      January 1, 2012 to December 31, 2015) and a 6-month follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All adults subjects living in the five well-defined areas affiliated to the French National
      Health Insurance System and having had at least one reimbursement of any antithrombotic in
      the 3-year study period are identified by using data from the National Health reimbursement
      database (Système National d'Information Inter-Régimes de l'Assurance Maladie, SNIIR-AM).
      SNIIR-AM contains individualized, anonymous and comprehensive data for all health spending
      reimbursements of affiliated subjects, including basic patient demographic data, medical
      drugs as well as outpatient medical care, prescribed or performed by health-care
      professionals from both public and private practices. This allows to calculate a denominator
      (number of person-years of anti-thrombotic drug exposure).

      Crude incidence rates of major bleeding per 100 person-months are calculated in
      antithrombotic users, anticoagulants and others; stratification on a modified HAS-BLED score
      allows fair comparison between anti-thrombotic drug classes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1, 2013</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of the risk of major bleeding of all classes of antithrombotic drugs, in particular the risk of major bleeding of anticoagulants, vitamin K antagonist (VKA) and direct oral anticoagulants (DOAC), in real clinical practice</measure>
    <time_frame>6 months</time_frame>
    <description>Unstable hemodynamic (systolic arterial pressure &lt; 90 mmHg or mean arterial pressure &lt; 65 mm Hg), hemorrhagic shock, uncontrollable bleeding, need for transfusions, need for haemostatic procedure (embolization, endoscopic procedure, surgery), or a life-threatened location of bleeding such as intracranial, intra-spinal, intraocular, retroperitoneal, pericardial, thoracic, intra-articular, intramuscular hematoma with compartment syndrome, acute gastrointestinal bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving treatment for drug-induced haemorrhage</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status after major bleeding</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status after major bleeding</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6484</enrollment>
  <condition>Major Haemorrhage</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antithrombotic</intervention_name>
    <description>Collection of clinical, biological data</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with major bleeding events associated with antithrombotic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with major bleeding event associated with antithrombotic drug

          -  Patient older than 18 years old

          -  Information on 1 and 6-month follow-up is given pending non-opposition letter

        Exclusion Criteria:

          -  Patients with major bleeding events associated with antithrombotic during
             hospitalization

          -  Patients with intentional overdose with antithrombotic drugs

          -  Patients with multi-trauma

          -  Patients living outside the defined influence areas of the five participating cities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinique de l'Anjou</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Inter-Armées</name>
      <address>
        <city>Brest</city>
        <zip>29 240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29 609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Sévigné</name>
      <address>
        <city>Cesson Sévigné</city>
        <zip>35576</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Echirolles</city>
        <zip>38432</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantaises</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé</name>
      <address>
        <city>Saint Grégoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major haemorrhage</keyword>
  <keyword>Oral anticoagulation</keyword>
  <keyword>Antiplatelet drugs</keyword>
  <keyword>Gastrointestinal bleeding</keyword>
  <keyword>Intracranial haemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

